<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111096">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02096965</url>
  </required_header>
  <id_info>
    <org_study_id>11-001780</org_study_id>
    <nct_id>NCT02096965</nct_id>
  </id_info>
  <brief_title>Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study</brief_title>
  <official_title>Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators propose to use a daily dose of 45 mg (30 mg at 8 AM and 15
      mg at 4 PM). This relatively small well-tolerated dose is likely to persistently increase
      urine volume and reduce urine supersaturation and to be well tolerated by patients with
      kidney stone disease and normal renal function (see below). The twice-daily (8 AM and 4 PM)
      regimen is designed to produce a maximal AVP inhibition on waking with a gradual fall-off of
      effect during the night. To this end, a higher dose is used in the morning, with a lower
      dose in the afternoon.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change in urinary calcium oxalate supersaturation (SS)</measure>
    <time_frame>Baseline to 3 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Calcium oxalate (CaOx) SS is primary endpoint for CaOx stone formers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Calcium phosphate SS</measure>
    <time_frame>Baseline to three weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Calcium phosphate (CaPhos) SS is the primary endpoint for CaPhos stone formers.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Nephrolithiasis, Calcium Oxalate</condition>
  <condition>Nephrolithiasis, Calcium Phosphate</condition>
  <arm_group>
    <arm_group_label>Tolvaptan first, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tolvaptan twice daily in first intervention period and placebo twice daily in second intervention period. (after washout period)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first, then Tolvaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo twice daily in first intervention period and Tolvaptan twice daily in second intervention period. (after washout period)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>Patients will receive daily dose of 45 mg (30 mg at 8 AM and 15 mg at 4 PM).</description>
    <arm_group_label>Tolvaptan first, then Placebo</arm_group_label>
    <arm_group_label>Placebo first, then Tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive daily dose at 8 AM and at 4 PM.</description>
    <arm_group_label>Tolvaptan first, then Placebo</arm_group_label>
    <arm_group_label>Placebo first, then Tolvaptan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of calcium oxalate or calcium phosphate stone.

          -  Good renal function

        Exclusion Criteria:

          -  History of hypo-or hypernatremia.

          -  History of hypotension or orthostatic dizziness.

          -  Clinical history of congestive heart failure.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Lieske, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth A. Kraft</last_name>
    <phone>507-266-8133</phone>
    <email>kraft.ruth@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth A. Kraft, Research Coordinator</last_name>
      <phone>507-266-8133</phone>
      <email>kraft.ruth@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Dr. John Lieske, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John Lieske</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Calcium oxalate</keyword>
  <keyword>Calcium phosphate</keyword>
  <keyword>Kidney stone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nephrolithiasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
